Investing in Bausch Health Cos Inc. (BHC)  ➔  Intrinsic value

Prev. close$27.92 
ModelValueUpside
Chepakovich$0.00-100%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$27.92  
Valuation MethodValuePotential 
Chepakovich Model$0.00-100%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

11 May

New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression => CNW Group 6:59AM

10 May

Were Hedge Funds Right About Piling Into Bausch Health Companies Inc. (BHC)? => Insider Monkey 4:32PM

6 May

Bausch Health Announces Participation In Upcoming Investor Conferences => PR Newswire 7:00AM

Bausch Health Announces Participation In Upcoming Investor Conferences => CNW Group 7:00AM

5 May

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss => Zacks 11:51AM

Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI™ => CNW Group 6:55AM

2 Top Turnaround Stocks to Buy Now => Motley Fool 6:30AM

4 May

Why Bausch Health Stock Is Falling Today => Motley Fool 11:39AM

Bausch Health Misses Estimates In 1Q; Shares Plunge 10% => SmarterAnalyst 11:26AM

2 Top Value Stocks to Buy in May => Motley Fool 10:46AM

Bausch Health (BHC) Beats Q1 Earnings Estimates => Zacks 8:20AM

Bausch reports a $610 million loss in the first quarter of the year => MarketWatch 7:52AM

Bausch Health Companies Inc. Announces First-Quarter 2021 Results => CNW Group 6:59AM

Bausch Health Cos., Inc. to Host Earnings Call => ACCESSWIRE 6:15AM

3 May

Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis => GlobeNewswire 7:05AM

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations => PR Newswire 7:00AM

30 Apr

Top 10 Value Stocks to Invest In According to ValueAct Capital => Insider Monkey 12:47PM

10 Best Value Stocks to Buy Right Now According to Value Investor Martin D. Sass => Insider Monkey 10:29AM

29 Apr

Bausch Health Exploring Potential Divestiture Of Eye Care Units: Bloomberg => Benzinga 12:36PM

Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting => PR Newswire 6:59AM

28 Apr

Bausch Health exploring potential sale of eye-care business - Bloomberg News => Reuters 5:33PM

Bausch Health to Explore Potential Sale of Its Eye-Care Unit => Bloomberg 3:45PM

Bausch Health Announces 2021 Annual Meeting of Shareholder Results => PR Newswire 7:00AM

27 Apr

Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation => CNW Group 7:00AM

22 Apr

Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris => PR Newswire 6:59AM

21 Apr

Ortho Dermatologics to Present New Data at the 2021 American Academy of Dermatology Annual Meeting => PR Newswire 6:59AM

Here's Why Bausch Health Companies Inc.'s (NYSE:BHC) CEO Compensation Is The Least Of Shareholders' Concerns => Simply Wall St. 1:19AM

16 Apr

Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil => PR Newswire 7:00AM

15 Apr

New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic => CNW Group 7:00AM

13 Apr

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery => Zacks 9:02AM

Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction => CNW Group 6:58AM

Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction => PR Newswire 6:58AM

10 Apr

3 Distressed Stocks for Contrarian Investors to Buy in April => Motley Fool 6:00AM

9 Apr

Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4 => CNW Group 7:00AM

8 Apr

Bausch Health Launches ENVIVE™ Daily Probiotic Supplement => PR Newswire 7:00AM

7 Apr

Bausch Health to reduce debt by $100 million using cash from operations => MarketWatch 7:35AM

FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device => PR Newswire 7:30AM

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations => CNW Group 7:00AM

2 Apr

Bausch Health Sells Amoun Pharmaceuticals For $740 Million => SmarterAnalyst 5:21AM

31 Mar

Bausch Health Agrees To Sell Amoun Pharmaceuticals => CNW Group 8:00AM

Company description

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.